DRL bets big on biosimilars Times of India The company in its annual report 2013 said that it has already produced four biosimilars - rituximab called Reditux TM, filgrastim called Grafeel, darbepoetin alpha called Cresp and peg-filgrastim called Peg-Grafeel. The company had even entered into ... |
